Cargando…
Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cy...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531270/ https://www.ncbi.nlm.nih.gov/pubmed/33072589 http://dx.doi.org/10.3389/fonc.2020.562625 |
_version_ | 1783589730478194688 |
---|---|
author | Keiffer, Gina French, Zachary Wilde, Lindsay Filicko-O'Hara, Joanne Gergis, Usama Binder, Adam F. |
author_facet | Keiffer, Gina French, Zachary Wilde, Lindsay Filicko-O'Hara, Joanne Gergis, Usama Binder, Adam F. |
author_sort | Keiffer, Gina |
collection | PubMed |
description | While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital. |
format | Online Article Text |
id | pubmed-7531270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75312702020-10-17 Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia Keiffer, Gina French, Zachary Wilde, Lindsay Filicko-O'Hara, Joanne Gergis, Usama Binder, Adam F. Front Oncol Oncology While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital. Frontiers Media S.A. 2020-09-18 /pmc/articles/PMC7531270/ /pubmed/33072589 http://dx.doi.org/10.3389/fonc.2020.562625 Text en Copyright © 2020 Keiffer, French, Wilde, Filicko-O'Hara, Gergis and Binder. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Keiffer, Gina French, Zachary Wilde, Lindsay Filicko-O'Hara, Joanne Gergis, Usama Binder, Adam F. Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title | Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title_full | Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title_fullStr | Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title_full_unstemmed | Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title_short | Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia |
title_sort | case report: tocilizumab for the treatment of sars-cov-2 infection in a patient with aplastic anemia |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531270/ https://www.ncbi.nlm.nih.gov/pubmed/33072589 http://dx.doi.org/10.3389/fonc.2020.562625 |
work_keys_str_mv | AT keiffergina casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia AT frenchzachary casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia AT wildelindsay casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia AT filickooharajoanne casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia AT gergisusama casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia AT binderadamf casereporttocilizumabforthetreatmentofsarscov2infectioninapatientwithaplasticanemia |